The objective of the clinical study is to evaluate the tolerability, safety, immunogenicity and prophylactic efficacy of the EpiVacCorona vaccine in 3,000 volunteers aged 18 and above.

The study tasks are to:

evaluate the safety of the EpiVacCorona vaccine when administered twice intramuscularly;

evaluate the tolerability of the EpiVacCorona vaccine when administered twice intramuscularly;

identify any adverse events to the administration of the EpiVacCorona vaccine;

investigate the humoral immune response following two doses of the EpiVacCorona vaccine;

investigate the cell-mediated immune response following two doses of the EpiVacCorona vaccine;

evaluate the prophylactic efficacy of the EpiVacCorona vaccine when administered twice intramuscularly.